SAN DIEGO, Feb. 15 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. , a biopharmaceutical company committed to the discovery, development and commercialization of novel medicines for the treatment of hepatitis and cancer, announced today that it will report fourth quarter and year-end 2006 financial results on Thursday, February 22, 2007, after the U.S. financial markets close.
Anadys will hold a conference call and webcast to discuss its fourth quarter and year-end financial results and operational highlights on Thursday, February 22, 2007 at 5:00 p.m. Eastern Standard Time. To access the webcast via the Internet, log on to www.anadyspharma.com. A telephone replay will be available approximately one hour after completion of the conference call. To access the telephone replay, dial (888) 286-8010 (domestic) or (617) 801-6888 (international), passcode 60505261. The webcast and telephone replay will be available through March 1, 2007.
About Anadys
Anadys Pharmaceuticals, Inc., www.anadyspharma.com, is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company has core expertise in developing Toll-Like Receptor-based small molecule therapeutics and utilizing structure-based drug design coupled with medicinal chemistry to identify new product candidates. Anadys is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys’ actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Risk factors that may cause actual results to differ are discussed in Anadys’ SEC filings, including Anadys’ Form 10-K for the year ended December 31, 2005 and the “Risk Factors” section of Anadys’ Form 10-Q for the quarter ended September 30, 2006. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.
CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications of Anadys Pharmaceuticals, Inc., +1-858-530-3653,vreardon@anadyspharma.com
Web site: http://www.anadyspharma.com/
